SCHEMBL30148439

SCHEMBL30148439

CCOC(=O)c1c(NC(=O)C2CC23CC3)sc2c1C[C@@H](N)CC2

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 9/20 0.52
ALDH1A1 P00352 6/20 0.52
LMNA P02545 3/20 0.52
KDM4E B2RXH2 6/20 0.50
HTT P42858 1/20 0.48
KMT2A Q03164 1/20 0.48
CNR1 P21554 1/20 0.48
CNR2 P34972 1/20 0.48
GAA P10253 2/20 0.46
TSHR P16473 3/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
POLB P06746 1/20 0.44
THRB P10828 1/20 0.44
NPSR1 Q6W5P4 2/20 0.44
HSD17B10 Q99714 2/20 0.44
ALOX15 P16050 1/20 0.44
HPGD P15428 2/20 0.43
MAPK1 P28482 1/20 0.43
BLM P54132 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28610570 0.90 KDM4E (0.52) MAPTALDH1A1LMNAKDM4EHTT
SCHEMBL21597779 0.86 KMT2A (0.59) MAPTALDH1A1LMNAKDM4EHTT
SCHEMBL21597574 0.84 PTPN1 (0.40) MAPTALDH1A1LMNAKDM4EKMT2A
SCHEMBL28611808 0.84 KMT2A (0.51) MAPTALDH1A1LMNAKDM4EHTT
SCHEMBL28610544 0.83 KDM4E (0.57) MAPTALDH1A1LMNAKDM4EHTT
SCHEMBL30148401 0.83 MAPT (0.47) MAPTALDH1A1LMNAKDM4EHTT
SCHEMBL28610613 0.82 MAPT (0.55) MAPTALDH1A1LMNAKDM4EHTT
SCHEMBL28610753 0.82 MAPT (0.55) MAPTALDH1A1LMNAKDM4EHTT
SCHEMBL28607607 0.81 KDM4E (0.53) MAPTALDH1A1LMNAKDM4EHTT
SCHEMBL28607611 0.81 KDM4E (0.53) MAPTALDH1A1LMNAKDM4EHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12018021-B2 Thiophene derivatives for the treatment of disorders caused by IgE UCB Biopharma SRL (BE) 2024-06-25 US disclosed
US-20220332709-A1 Thiophene derivatives for the treatment of disorders caused by IgE UCB Biopharma SRL (BE) 2022-10-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220332709-A1 Thiophene derivatives for the treatment of disorders caused by IgE TSLP, CYSLTR1, CYSLTR2 MAPT 2356/4885ALDH1A1 233/4885LMNA 4878/4885
US-12018021-B2 Thiophene derivatives for the treatment of disorders caused by IgE TSLP, CYSLTR1, CYSLTR2 MAPT 2356/4885ALDH1A1 233/4885LMNA 4878/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.